PURPOSE: To identify a dose of the demethylating agent 5-aza-2'-deoxycytidine (DAC) with acceptable side effects, and to study its effect on the methylation patterns of relevant genes in tumor biopsies before and after treatment with a novel methylation assay using real-time PCR. METHODS: A group of 19 patients with metastatic solid tumors were treated with DAC by continuous intravenous infusion over 72 h, days 1-3 of a 28-day cycle. Tumor biopsies were taken before and 7 days after starting DAC. RESULTS: The dose levels studied were 20, 30 and 40 mg/m(2). Grade 4 neutropenia was found in two of five patients at 40 mg/m(2) and one of six patients at 30 mg/m(2). No objective responses were seen in this study. Steady-state DAC levels of 0.1 to 0.2 microM were achieved in the 30 and 40 mg/m(2) cohorts. Changes in methylation were observed, but no single gene consistently demonstrated evidence of demethylation. CONCLUSIONS:DAC was tolerated at a dose of 30 mg/m(2) per day for a 72-h intravenous infusion. Changes in gene methylation were observed.
RCT Entities:
PURPOSE: To identify a dose of the demethylating agent 5-aza-2'-deoxycytidine (DAC) with acceptable side effects, and to study its effect on the methylation patterns of relevant genes in tumor biopsies before and after treatment with a novel methylation assay using real-time PCR. METHODS: A group of 19 patients with metastatic solid tumors were treated with DAC by continuous intravenous infusion over 72 h, days 1-3 of a 28-day cycle. Tumor biopsies were taken before and 7 days after starting DAC. RESULTS: The dose levels studied were 20, 30 and 40 mg/m(2). Grade 4 neutropenia was found in two of five patients at 40 mg/m(2) and one of six patients at 30 mg/m(2). No objective responses were seen in this study. Steady-state DAC levels of 0.1 to 0.2 microM were achieved in the 30 and 40 mg/m(2) cohorts. Changes in methylation were observed, but no single gene consistently demonstrated evidence of demethylation. CONCLUSIONS:DAC was tolerated at a dose of 30 mg/m(2) per day for a 72-h intravenous infusion. Changes in gene methylation were observed.
Authors: Rani E George; Jill M Lahti; Peter C Adamson; Kejin Zhu; David Finkelstein; A Mark Ingle; Joel M Reid; Mark Krailo; Donna Neuberg; Susan M Blaney; Lisa Diller Journal: Pediatr Blood Cancer Date: 2010-10 Impact factor: 3.167
Authors: Mazin Al-Salihi; Margaret Yu; David M Burnett; Amanda Alexander; Wolfram E Samlowski; Frank A Fitzpatrick Journal: Epigenetics Date: 2011-08-01 Impact factor: 4.528
Authors: Fang Fang; Joanne Munck; Jessica Tang; Pietro Taverna; Yinu Wang; David F B Miller; Jay Pilrose; Gavin Choy; Mohammad Azab; Katherine S Pawelczak; Pamela VanderVere-Carozza; Michael Wagner; John Lyons; Daniela Matei; John J Turchi; Kenneth P Nephew Journal: Clin Cancer Res Date: 2014-10-14 Impact factor: 12.531
Authors: Oscar Alcazar; Susan Achberger; Wayne Aldrich; Zhenbo Hu; Soledad Negrotto; Yogen Saunthararajah; Pierre Triozzi Journal: Int J Cancer Date: 2011-09-06 Impact factor: 7.396
Authors: Floor A M Duijkers; Renee X de Menezes; Inès J Goossens-Beumer; Dominique J P M Stumpel; Pieter Admiraal; Rob Pieters; Jules P P Meijerink; Max M van Noesel Journal: Cell Oncol (Dordr) Date: 2013-07-18 Impact factor: 6.730